Peter Geschek
Long only

Portola's Antidote Could Benefit Pfizer, Bristol-Myers, J&J

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has been granted Breakthrough Therapy designation by the FDA in November for andexanet alfa (formerly PRT4445), its investigational Factor Xa inhibitor antidote.

The creation of this antidote is a big deal that can affect the lives of millions of people around the world.

A new generation of anticoagulants on the market, the so called Factor Xa inhibitors have shown substantial advantages over current standard therapies, such as the warfarin and enoxaparin.

However, physicians need a rapid reversal agent for patients who start bleeding or require urgent surgery. As it stands, no such antidote exists.

Although bleeding events occur infrequently (1-4 percent in clinical studies), the absolute number globally is really large due to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details